Tenax Therapeutics (TENX) Cash from Financing Activities (2010 - 2026)

Tenax Therapeutics (TENX) has 15 years of Cash from Financing Activities data on file, last reported at $30.5 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities rose 29.44% year-over-year to $30.5 million; the trailing twelve-month figure through Mar 2026 stood at $45.4 million (down 60.65% YoY), and the FY2025 full-year result was $38.5 million, down 61.44% from the prior year.
• Cash from Financing Activities improved to $30.5 million in Q1 2026, from $11.6 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $92.0 million in Q3 2024 to a low of -$174603.0 in Q4 2023.
• A 5-year average of $11.2 million and a median of $278000.0 in 2025 frame the typical range for Cash from Financing Activities.
• Across the five-year window, Cash from Financing Activities plunged 8563.55% in 2023 and surged 53820.45% in 2024, its largest moves.
• Tracing TENX's Cash from Financing Activities over 5 years: stood at $2063.0 in 2022, then sank by 8563.55% to -$174603.0 in 2023, then soared by 138.37% to $67000.0 in 2024, then surged by 17229.85% to $11.6 million in 2025, then jumped by 162.67% to $30.5 million in 2026.
• Business Quant data shows TENX's Cash from Financing Activities at $30.5 million in Q1 2026, $11.6 million in Q4 2025, and $3.1 million in Q3 2025.